The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of "genetic surgery" is performed on DNA, for ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

Researchers at San Diego State University and Michigan State University are shedding new light on how viruses meticulously ...

As aging progresses, the quality of DNA and proteins inside cells declines, which is known to be the cause of various ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Xenium Protein, a ...

Using artificial intelligence, MIT researchers have come up with a new way to design nanoparticles that can more efficiently ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

A high-level overview of Avidity Biosciences, Inc. (RNA) stock. View (RNA) real-time stock price, chart, news, analysis, analyst reviews and more.